Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG MS Study.

Lauren B KruppBrenda BanwellTanuja ChitinisKumaran DeivaJutta GaertnerAngelo GhezziPeter HuppkeEmmanuelle WaubantVirginia DeLasHerasAmin AzmonRajesh Karan

Published in: BMJ neurology open (2022)

Fingolimod improved HRQoL compared with IFN β-1a in patients with PoMS as evidenced by the self-reported and parent-reported PedsQL scores.

Keyphrases

multiple sclerosis
emergency department
intensive care unit
mass spectrometry